Drug Delivery for Enhanced Bioavailability of BCS2 (Poorly Soluble) Compounds

Drug Delivery for Enhanced Bioavailability of BCS2 (Poorly Soluble) Compounds
Product Description

Engineered to bring together advanced silica technologies with challenging active pharmaceutical ingredients (APIs) to effectively formulate a large class of poorly soluble but otherwise promising compounds, Grace’s SILSOL® silica-based drug delivery technology provides solutions for poorly soluble active ingredients. Combining our expertise in mesoporous silica gel, novel application methods, and patented technologies, SILSOL® silica can provide solutions for acceleration of the screening and development of solubility enhancing solid dispersions, with the added benefit of doing so with compendial, scalable, and available silicas.

W. R. Grace & Co

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

W. R. Grace & Co

  • US
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator

More Products from W. R. Grace & Co (4)

  • Custom Fine Chemical Manufacturing

    Product Custom Fine Chemical Manufacturing

    Our comprehensive portfolio of services, integrated manufacturing, and regulatory leadership differentiates us as a leading contract development and manufacturing partner. With a proven ability to deliver solutions to complex challenges, Grace’s FCMS supports the entire small molecule development cycle from t...
  • Purification and Formulation of Oily APIs and Omega-3s

    Product Purification and Formulation of Oily APIs and Omega-3s

    Grace resins and excipients improve purity and create better targeted and higher value formulations with enhanced bioavailability. Grace is solving purification and formulation issues in oily APIs and Omega-3s in high quality separation capabilities, customization, reliability and speed to market, and com...
  • Purification and Formulation of Cannabinoids (CBD)

    Product Purification and Formulation of Cannabinoids (CBD)

    Grace has developed and introduced a patented silica based carrier, SYLOID® XDP silica, to directly convert liquid ingredients such as CBD into solid dosage forms. Extracting and purifying CBD from the hemp plant is a multi-step process which focuses on removal of several undesirable impurities. Grace has...
  • Custom Bonding and Chromatography Resins for Small and Large Molecule Purification

    Product Custom Bonding and Chromatography Resins for Small and Large Molecule Purification

    A wide range of DAVISIL® silica gel grades are available from one kg to multi-ton quantities to meet your application, performance, and economic requirements. DAVISIL® silicas are used to purify nutraceuticals, antibiotics, vaccine adjuvants, oil-based APIs, organic synthesis products (including intermediates...

W. R. Grace & Co resources (3)

  • News Grace Completes Acquisition of Fine Chemistry Business

    June 01, 2021: W. R. Grace & Co. announced the completion of its acquisition of the Fine Chemistry Services business (“FCS”) of Albemarle Corporation (NYSE: ALB) for approximately $570 million, including $300 million paid in cash and $270 million funded through the issuance to Albemarle of non-participating preferred equity of a newly created Grace subsidiary.
  • Brochure Grace Pharmaceutical Solutions Brochure

    Learn more about Grace's unmatched quality and reproducibility of our fine chemicals, chromatography resins, formulation excipients, and active ingredient delivery technologies.
  • Video Natural Extracts: Unlocking the Potential of Cannabinoid Derived Drugs

    Originally aired during the CPHI Festival of Pharma 2020, this webinar examines the current landscape for cannabinoid derived drugs, including looking at pipeline and approvals, development challenges and regulatory hurdles.